

November 27, 2021

To,

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400 001

National Stock Exchange of India Limited

Listing Department
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip code: 512529

Symbol: SEQUENT

Subject: Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended September 30, 2021.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



Krunal Shah
Company Secretary & Compliance Officer



Encl.: As above

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area,
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Disclosure of related party transactions on consolidated basis

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

A List of related parties

List of related parties with whom transactions have taken place during the period ended 30 September 2021

a) Key management personnel (KMP)

Mr. Manish Gupta, Chief Executive Officer & Managing Director
Mr. Sharat Narasapur, Joint Managing Director
Mr. Tushar Mistry, Chief Financial Officer
Mr. Krunal, Shah, Company Secretary
Dr. Kamal K Sharma, Independent Director
Mr. Milind Sarwate, Independent Director
Mr. Gregory Andrews John, Non-Executive Director
Dr. Fabian Kausche, Non-Executive Director
Dr. Kausalya Santhanam, Independent Director

b) Transactions with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries (refer note as below)

Strides Pharma Sciences Limited (formerly known as Strides Shasun Limited)
Strides Emerging Markets Limited
Tenshi Kaizen Private Limited
Stelis Biopharma Private Limited
Solara Active Pharma Sciences Limited
Sequent Penems Private Limited

Note: Subsequent to change of control in the SeQuent Scientific Limited, the above entities have ceased to be related parties w.e.f. 17 August 2020 under the Companies Act, 2013. The Company had filed requisite application with the Stock Exchanges as prescribed under SEBI LODR regulations seeking re-classification of the erstwhile 'Promoter Group' into 'Public Category' and the Stock Exchange approval for the same was received on 01 November 2021.




Kushal

B Transactions during the period 01 April 2021 to 30 September 2021

Particulars	₹ in Million
i) Transactions with KMP	
Managerial remuneration (*)	
Mr. Manish Gupta	
Short Term Benefits	13.26
Share based payments	15.30
Mr. Sharat Narsapur	
Short Term Benefits	5.07
Mr. Tushar Mistry	
Short Term Benefits	4.62
Mr. Krunal Shah	
Short Term Benefits	0.87
Directors sitting fees	
Dr. Kamal K Sharma	1.60
Mr. Milind Sarwate	1.30
Mr. Gregory Andrews John	0.20
Dr. Fabian Kausche	0.20
Dr. Kausalya Santhanam	0.20
ii) Transaction with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries	
Sale of materials/services	
Strides Pharma Sciences Limited	0.10
Strides Emerging Markets Limited	0.16
Solara Active Pharma Sciences Limited	41.65
Stelis Biopharma Private Limited	0.08
Tenshi Kaizen Private Limited	0.13
Purchase of materials	
Solara Active Pharma Sciences Limited	107.33
Commission expenses	
Solara Active Pharma Sciences Limited	0.05
Payment towards lease obligation and finance costs	
Solara Active Pharma Sciences Limited	4.41
Security deposit recovered from	
Sequent Penems Private Limited	0.29
iii) Balance as at 30 September 2021	
Trade Receivables / other current assets	
Strides Pharma Sciences Limited	0.05
Strides Emerging Markets Limited	0.27
Solara Active Pharma Sciences Limited	9.60
Stelis Biopharma Private Limited	0.06
Security deposit receivable	
Solara Active Pharma Sciences Limited	4.20
Trade payables	
Solara Active Pharma Sciences Limited	19.06

(*) Expenses towards gratuity and compensated absences provisions are determined actuarially on an overall Group basis at the end of each year and accordingly have not been considered in the above information.


Tushar Mistry
Chief Financial Officer


Krunal Shah
Company Secretary



Place: Thane
Date: 27 November 2021